• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

5.190 +0.310 (+6.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
June 25, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
May 28, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
May 27, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
May 12, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
April 27, 2026
Via MarketBeat
Topics Government
News headline image
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
April 27, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
April 21, 2026
Via Chartmill
News headline image
Why AtaiBeckley Stock Surged Today ↗
April 20, 2026
President Trump wants to fast-track psychedelic research. 
Via The Motley Fool
Topics Government
News headline image
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
April 20, 2026
Via AB Newswire
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
April 20, 2026
Via MarketBeat
News headline image
AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating ↗
April 20, 2026
AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews. 
Via Benzinga
Topics Government
What's going on in today's session ↗
April 20, 2026
Via Chartmill
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
April 20, 2026
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
April 20, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
April 20, 2026
Via Chartmill
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
March 26, 2026
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
March 24, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
March 17, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
March 10, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
March 09, 2026
Via AB Newswire
News headline image
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
March 06, 2026
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
March 03, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
February 26, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
February 20, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
February 19, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Participate in Upcoming Investor Conferences
February 17, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
January 19, 2026
Via MarketBeat
News headline image
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
January 16, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
January 08, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
January 05, 2026
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap